PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Neprilysin Inhibitors in Cardiovascular Disease.

Abstract Mortality from heart failure remains high despite advances in medical therapy over the last three decades. Angiotensin receptor-neprilysin inhibitor (ARNI) combinations are the latest addition to the heart failure medical armamentarium, which is built on the cornerstone regimen of beta blockers, angiotensin converting enzyme (ACE) inhibitors/angiotensin receptor blockers, and aldosterone antagonists. Recent trial data have shown a significant mortality benefit from ARNIs, which, as of May 2016, have now received a class I recommendation for use in patients with heart failure and reduced ejection fraction from the major American and European cardiology societies.
PMID
Related Publications

Sacubitril/valsartan (LCZ696) for the treatment of heart failure.

Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.

Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF).

Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.

Combined angiotensin receptor/neprilysin inhibitors: a review of the new paradigm in the management of chronic heart failure.

Authors

Mayor MeshTerms
Keywords

Heart failure

LCZ696

Neprilysin inhibitor

Sacubitril

Journal Title current cardiology reports
Publication Year Start




PMID- 28185171
OWN - NLM
STAT- In-Data-Review
DA  - 20170210
LR  - 20170210
IS  - 1534-3170 (Electronic)
IS  - 1523-3782 (Linking)
VI  - 19
IP  - 2
DP  - 2017 Feb
TI  - Neprilysin Inhibitors in Cardiovascular Disease.
PG  - 16
LID - 10.1007/s11886-017-0827-0 [doi]
AB  - Mortality from heart failure remains high despite advances in medical therapy
      over the last three decades. Angiotensin receptor-neprilysin inhibitor (ARNI)
      combinations are the latest addition to the heart failure medical armamentarium, 
      which is built on the cornerstone regimen of beta blockers, angiotensin
      converting enzyme (ACE) inhibitors/angiotensin receptor blockers, and aldosterone
      antagonists. Recent trial data have shown a significant mortality benefit from
      ARNIs, which, as of May 2016, have now received a class I recommendation for use 
      in patients with heart failure and reduced ejection fraction from the major
      American and European cardiology societies.
FAU - Kang, Guson
AU  - Kang G
AD  - Division of Cardiovascular Medicine, Department of Medicine, Stanford University,
      Falk Cardiovascular Research Center, 870 Quarry Road, Palo Alto, CA, 94304, USA. 
      [email protected]
FAU - Banerjee, Dipanjan
AU  - Banerjee D
AD  - Division of Cardiovascular Medicine, Department of Medicine, Stanford University,
      Falk Cardiovascular Research Center, 870 Quarry Road, Palo Alto, CA, 94304, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Cardiol Rep
JT  - Current cardiology reports
JID - 100888969
OTO - NOTNLM
OT  - Heart failure
OT  - LCZ696
OT  - Neprilysin inhibitor
OT  - Sacubitril
EDAT- 2017/02/12 06:00
MHDA- 2017/02/12 06:00
CRDT- 2017/02/11 06:00
AID - 10.1007/s11886-017-0827-0 [doi]
AID - 10.1007/s11886-017-0827-0 [pii]
PST - ppublish
SO  - Curr Cardiol Rep. 2017 Feb;19(2):16. doi: 10.1007/s11886-017-0827-0.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>